home
about us
our story
FUNDING & GRANTS
OUR SCIENTIFIC CO-FOUNDERS
OUR MANAGEMENT
OUR BOARD
science
F prau.
in Iflammatory Bowel Diseases
F prau.
in Cancer
MANUFACTURING LIVE BIOThERAPEUTICS
pipeline
Overview
Patients
Exl01 in Crohn's diseases
Exl01 in Cancer Immunotherapy
newsroom
PUBLICATIONS
contact
menu
about us
about us
Our story
funding & grants
Our Scientific Co-founders
Our mission
Our values
Our management
Our board
Talents
science
science
Exl01
Crohn's Disease
Faecalibacterium Prausnitzii
in Inflammatory Bowel Diseases
Faecalibacterium Prausnitzii
immuno-oncology
Faecalibacterium Prausnitzii
in Recurrent
Clostridium difficile
Infections
Tryptophan metabolism
Manufacturing Live Biotherapeutics
pipeline
pipeline
EXL01’s description & clinical trials
Patients
EXL01 in Crohn’s Disease
EXL01 in Cancer Immunotherapy
EXL01 in Immuno-Oncology
EXL01 in recurrent
Clostridium difficile
infections
EXL02
EXL03
Regulatory Expertise
Intellectual Property
newsroom
newsroom
Corporate Presentation
Publications
News
Upcoming Events
contact
Nextbiotix Exeliom Biosciences
Feb 15, 2019
Nextbiotix becomes Exeliom Biosciences
Back to news
Apr 27, 2023
SATT Paris-Saclay and Exeliom Biosciences Sign License Option Agreement to Develop Breakthrough Recombinant Protein Targeting Tryptophan Metabolism
Explore
Apr 11, 2024
Exeliom Biosciences announces three phase II clinical trials in immuno-oncology with lead candidate combined with immune checkpoint inhibitors
Explore
Jun 25, 2024
Exeliom Biosciences collaborates with REMIND in MAINTAIN POP study
Explore
contact
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
%20Pamela%20Chemla.jpg)
